198.23
-0.70 (-0.35%)
| Previous Close | 198.93 |
| Open | 198.71 |
| Volume | 1,636,658 |
| Avg. Volume (3M) | 1,240,098 |
| Market Cap | 27,206,692,864 |
| Price / Sales | 10.74 |
| Price / Book | 17.64 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -10.36% |
| Operating Margin (TTM) | -15.78% |
| Diluted EPS (TTM) | -1.47 |
| Quarterly Revenue Growth (YOY) | 36.50% |
| Total Debt/Equity (MRQ) | 15.78% |
| Current Ratio (MRQ) | 3.87 |
| Operating Cash Flow (TTM) | 153.12 M |
| Levered Free Cash Flow (TTM) | 120.93 M |
| Return on Assets (TTM) | -8.87% |
| Return on Equity (TTM) | -18.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Natera, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -5.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.50 |
|
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 3.24% |
| % Held by Institutions | 96.37% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 255.00 (RBC Capital, 28.64%) | Buy |
| Median | 225.00 (13.51%) | |
| Low | 175.00 (Wells Fargo, -11.72%) | Hold |
| Average | 217.88 (9.91%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 177.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 07 Nov 2025 | 230.00 (16.03%) | Buy | 199.57 |
| 23 Oct 2025 | 210.00 (5.94%) | Buy | 195.00 | |
| Barclays | 07 Nov 2025 | 230.00 (16.03%) | Buy | 199.57 |
| 08 Aug 2025 | 210.00 (5.94%) | Buy | 151.95 | |
| Evercore ISI Group | 07 Nov 2025 | 250.00 (26.12%) | Buy | 199.57 |
| Canaccord Genuity | 14 Oct 2025 | 200.00 (0.89%) | Buy | 172.81 |
| Wells Fargo | 22 Sep 2025 | 175.00 (-11.72%) | Hold | 179.19 |
| Stephens & Co. | 15 Aug 2025 | 183.00 (-7.68%) | Buy | 163.02 |
| Piper Sandler | 11 Aug 2025 | 220.00 (10.98%) | Buy | 157.04 |
| RBC Capital | 08 Aug 2025 | 255.00 (28.64%) | Buy | 151.95 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BROPHY MICHAEL BURKES | - | 191.53 | -5,063 | -967,912 |
| CHAPMAN STEVEN LEONARD | - | 190.90 | -6,015 | -1,146,451 |
| FESKO JOHN | - | 190.90 | -1,709 | -326,045 |
| MOSHKEVICH SOLOMON | - | 190.90 | -2,206 | -420,863 |
| RABINOWITZ DANIEL | - | 190.90 | -1,993 | -380,291 |
| SHEENA JONATHAN | - | 190.90 | -479 | -91,567 |
| Aggregate Net Quantity | -17,465 | |||
| Aggregate Net Value ($) | -3,333,128 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 191.04 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BROPHY MICHAEL BURKES | Officer | 29 Oct 2025 | Automatic sell (-) | 1,867 | 192.81 | 359,976 |
| RABINOWITZ DANIEL | Officer | 28 Oct 2025 | Automatic sell (-) | 1,058 | 189.57 | 200,565 |
| MOSHKEVICH SOLOMON | Officer | 28 Oct 2025 | Automatic sell (-) | 1,198 | 189.57 | 227,105 |
| FESKO JOHN | Officer | 28 Oct 2025 | Automatic sell (-) | 928 | 189.57 | 175,921 |
| SHEENA JONATHAN | Director | 28 Oct 2025 | Automatic sell (-) | 191 | 189.57 | 36,208 |
| BROPHY MICHAEL BURKES | Officer | 28 Oct 2025 | Automatic sell (-) | 2,415 | 189.57 | 457,812 |
| CHAPMAN STEVEN LEONARD | Officer | 28 Oct 2025 | Automatic sell (-) | 3,680 | 189.57 | 697,618 |
| RABINOWITZ DANIEL | Officer | 27 Oct 2025 | Automatic sell (-) | 935 | 192.22 | 179,726 |
| MOSHKEVICH SOLOMON | Officer | 27 Oct 2025 | Automatic sell (-) | 1,008 | 192.22 | 193,758 |
| FESKO JOHN | Officer | 27 Oct 2025 | Automatic sell (-) | 781 | 192.22 | 150,124 |
| SHEENA JONATHAN | Director | 27 Oct 2025 | Automatic sell (-) | 288 | 192.22 | 55,359 |
| BROPHY MICHAEL BURKES | Officer | 27 Oct 2025 | Automatic sell (-) | 781 | 192.22 | 150,124 |
| CHAPMAN STEVEN LEONARD | Officer | 27 Oct 2025 | Automatic sell (-) | 2,335 | 192.22 | 448,834 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |